The efficacy of immunotherapy against melanoma and colorectal cancer was enhanced by the simultaneous blocking of CD47 and PD-L1 using bispecific antibodies, which activated both innate and adaptive immune responses [53–55]. This evidence concerns the gene CD274 and melanoma.